These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38371479)

  • 1. Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.
    Lüthi H; Lengsfeld S; Burkard T; Meienberg A; Jeanloz N; Vukajlovic T; Bologna K; Steinmetz M; Bathelt C; Sailer CO; Laager M; Vogt DR; Hemkens LG; Speich B; Urwyler SA; Kühne J; Baur F; Lutz LN; Erlanger TE; Christ-Crain M; Winzeler B
    EClinicalMedicine; 2024 Feb; 68():102429. PubMed ID: 38371479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.
    Lengsfeld S; Burkard T; Meienberg A; Jeanloz N; Vukajlovic T; Bologna K; Steinmetz M; Bathelt C; Sailer CO; Vogt DR; Hemkens LG; Speich B; Urwyler SA; Kühne J; Baur F; Lutz LN; Erlanger TE; Christ-Crain M; Winzeler B
    EClinicalMedicine; 2023 Mar; 57():101865. PubMed ID: 36874396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study.
    Lengsfeld S; Burkard T; Meienberg A; Jeanloz N; Coynel D; Vogt DR; Hemkens LG; Speich B; Zanchi D; Erlanger TE; Christ-Crain M; Winzeler B
    Trials; 2023 Apr; 24(1):284. PubMed ID: 37081574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dulaglutide on alcohol consumption during smoking cessation.
    Probst L; Monnerat S; Vogt DR; Lengsfeld S; Burkard T; Meienberg A; Bathelt C; Christ-Crain M; Winzeler B
    JCI Insight; 2023 Nov; 8(22):. PubMed ID: 37991022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study.
    Lengsfeld S; Probst L; Emara Y; Werlen L; Vogt DR; Bathelt C; Baur F; Caviezel B; Vukajlovic T; Fischer M; Winzeler B
    EBioMedicine; 2024 Sep; 107():105284. PubMed ID: 39232425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varenicline for smoking cessation in individuals who smoke cigarettes and use electronic cigarettes: a double-blind, randomised, placebo-controlled phase 3 trial.
    Caponnetto P; Spicuzza L; Campagna D; Ahluwalia JS; Russell C; Maglia M; Riela PM; Longo CF; Caci G; Quattropani MC; Signorelli MS; Polosa R
    EClinicalMedicine; 2023 Dec; 66():102316. PubMed ID: 38192585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
    Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Urva S; Coskun T; Loh MT; Du Y; Thomas MK; Gurbuz S; Haupt A; Benson CT; Hernandez-Illas M; D'Alessio DA; Milicevic Z
    Lancet; 2022 Nov; 400(10366):1869-1881. PubMed ID: 36354040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial.
    King A; Vena A; de Wit H; Grant JE; Cao D
    JAMA Netw Open; 2022 Mar; 5(3):e220951. PubMed ID: 35244704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.
    Mercié P; Arsandaux J; Katlama C; Ferret S; Beuscart A; Spadone C; Duvivier C; Reynes J; Wirth N; Moinot L; Bénard A; Zucman D; Duval X; Molina JM; Spire B; Fagard C; Chêne G;
    Lancet HIV; 2018 Mar; 5(3):e126-e135. PubMed ID: 29329763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
    Anthenelli RM; Benowitz NL; West R; St Aubin L; McRae T; Lawrence D; Ascher J; Russ C; Krishen A; Evins AE
    Lancet; 2016 Jun; 387(10037):2507-20. PubMed ID: 27116918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial.
    Baur F; Atila C; Lengsfeld S; Burkard T; Meienberg A; Bathelt C; Christ-Crain M; Winzeler B
    BMJ Nutr Prev Health; 2023 Dec; 6(2):301-309. PubMed ID: 38264360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.
    Evins AE; Cather C; Pratt SA; Pachas GN; Hoeppner SS; Goff DC; Achtyes ED; Ayer D; Schoenfeld DA
    JAMA; 2014 Jan; 311(2):145-54. PubMed ID: 24399553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.
    Thomas KH; Dalili MN; López-López JA; Keeney E; Phillippo D; Munafò MR; Stevenson M; Caldwell DM; Welton NJ
    Health Technol Assess; 2021 Oct; 25(59):1-224. PubMed ID: 34668482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.